focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
BGF inv.man took a 5.6% stake announced late Friday. This looks very relevant as BGF have invested £1.9B since 2011 in small private growth companies. This is a rare occasion where they have invested in a PLC.
http://optibiotix.com/optibiotix-cholbiomex3-shortlisted-for-industry-award/
OptiBiotix CholBiome®X3 Shortlisted for Industry Award
NutraIngredients has named OptiBiotix revolutionary cholesterol management product, CholBiome®X3, as a finalist in the ‘Best Probiotic Product of The Year’ category of the 2019 awards.
Stephen O’Hara, OptiBiotix CEO, said: “We are delighted to receive this shortlisting, which reflects the growing consumer trend for more natural options with no side effects in managing cardiovascular risk. CholBiomeX3 is an important addition to the nutraceutical sector, developed using pharmaceutical platforms and with safety and efficacy proven in independent clinical studies carried out by leading Universities, we welcome the NutraIngredients Awards’ celebration of this.”
Harnessing the power of the patented probiotic Lactobacillus plantarum LPLDL®, backed by extensive award-winning science and using platforms based on pharmaceutical approaches, CholBiomeX3 is an ideal way to regulate cholesterol levels and promote heart health. It combines three key natural ingredients – LPLDL, Vitamin B3 and red yeast rice rich in Monacolin K to help reduce cholesterol levels, promote heart wellness and reduce blood pressure.
LPLDL has been found not only to reduce ‘bad’ LDL cholesterol by 13.9%, but also to boost ‘good’ HDL cholesterol by 4.5%. Unlike statins, which are often used to treat high cholesterol, clinical studies and widespread consumer use have shown LPLDL has no known side effects.
The NutraIngredients Awards recognise the creativity and innovation that is forging the future of the nutraceutical industry. The finalists will be showcased on the NutraIngredients stand at Vitafoods Europe 2019 for three days in May and the winners will be announced and presented with their trophies at a glittering awards dinner on Wednesday 8th May at the Starling Hotel, Geneva.
80% of sequencing done on Illumia's platform. Yourgene now a partner rather than an enemy.
Looks like another competitor in a spot of bother!
Illumina Sues BGI in Germany for Patent Infringement
Mar 29, 2019 | staff reporter
NEW YORK (GenomeWeb) – Illumina has filed a lawsuit against BGI Group subsidiary Latvia MGI Tech in the Düsseldorf Regional Court in Germany, alleging that BGI's sequencing products and related reagents infringe a patent Illumina holds in Europe, EP 1 530 578 B1, which covers sequencing-by-synthesis chemistry.'
"Illumina will not tolerate the unauthorized, infringing use of its patented technology," Charles Dadswell, senior vice president and general counsel for Illumina, said in a statement. "We will continue to monitor the field and file patent suits where appropriate when our patents are infringed."
Illumina said that the '578 European patent has previously been upheld and that its US counterpart patent was affirmed by the US Patent Trial and Appeal Board last year. BGI had petitioned for an inter partes review of Illumina's US Patent No.: 7,566,537 B2 in 2017, and in 2018 the PTAB denied BGI's request.
Illumina was also previously involved in patent disputes with Complete Genomics, before BGI acquired it, initially suing Complete Genomics in 2010 and then again in 2012. Those suits were ultimately settled in 2013.
The Latvia operations of MGI Tech were established to prepare the firm for instrument sales in Europe. MGI recently told GenomeWeb that the facility will become operational by the end of this year.
Concepta Plc secures partnership with Walgreens Boots Alliance!!
Peter Dines, Chief Operating Officer at Mercia and a non-executive director of Concepta, said: "Securing a partnership with such a leading retailer as Walgreens Boots Alliance is validation that Concepta has developed a product with significant commercial appeal. This new partnership will play a pivotal role in myLotus® being more widely available across the UK and overseas."
Concepta Bedfordshire-based Concepta was founded in 2013 by a group of people including two former employees of Unilever who had helped develop pregnancy tests there in the 1990s. Frustrated by the “qualitative” approach of pregnancy tests that measure hormone levels to generate a positive or negative result, Concepta’s executive chairman Matthew Walls said the company set out to create a “quantitative” test that would monitor in more detail how hormones change. For the past six years the company has been developing a device to do this, but “the developments had taken way longer than they should have”, he said. Finally, in the past six months, the company has found its first users: around 150 women who are using its ovulation and pregnancy tests to measure their hormone levels. The device feeds the results to a smartphone app so users can monitor their hormonal cycles. The long-term goal is to identify each woman’s regular hormonal cycle and alert her if it varies. “In a year or so, when we’ve filled out data banks, we will have really powerful data,” Mr Walls said. “That goes beyond what you learn at school [about how] the normal [menstrual] cycle is 28 days and you ovulate at day 14.” Concepta’s share price has fallen 42 per cent to 4p over the past year as investors wait for the product to come to market. https://amp.ft.com/content/a78a7078-418b-11e9-9bee-efab61506f44 Great to see some press coverage on CPT!
This low valuation can’t stay like this for long. Fincap price target of 18p is also a joke! IMHO 25p - 30p is more realistic on the basis of record trading alluded to in the last RNS.
YGEN has almost double from their Q4 low of last year - hopefully Concepta will do the same. Short term surely they could go through their 4p placing price..
https://www.premaitha.com/company/yourgene-bioscience
I know they bought these guys a while back, a name change can only be a positive thing IMO
Clearly Myers likes this company as he now has nearly 8%. I hear market sources say that he thinks Premaitha could be worth £500M within 2 years. My maths suggests it could be a 10 bagger from here!
This is looks very ugly sadly, I am hearing that damages could be in excess as �5M as well as additional penalties.
Yesterdays article; SkinBiotherapeutics readying for cosmetic cream launch after safety test success SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours SkinBioTherapeutics PLC (LON:SBTX) expects a study in people of a cosmetic skin care cream next year to be the start of �serious� commercialisation talks. Tentative discussions have already begun, Cath O�Neill, the skin microbiome specialist�s chief executive told Proactive Investors, but human data is crucial to the process. �Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.� WATCH:SkinBioTherapeutics' Dr Cath O'Neill named one of healthcare's top movers and shakers SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials. Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately. Work on the formulation of the skin cream has also started, O�Neill said, adding this was another crucial part of the product development process. SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours and now just has two more safety tests to clear before the human efficacy study can begin. SkinBioTherapeutics presented data recently at a microbiome symposium sponsored by Wellcome Trust that was well received, but the human trial will be a major step forward, she added. �Once the results [from the human study] are in we are good to go.� SkinBiotix might be either an ingredient in someone else�s product or a brand in its own right. O�Neill was talking to Proactive after being named among the top 50 female movers and shakers in the BioBusiness 2017 report. She said was delighted to receive the award especially as SkinbioTherapeutics was listed in the great science category. �SkinBioTherapeutics is founded on very robust science and is proud of its scientific heritage.� The company is working on three applications for its microbiome-based products: cosmetics; an anti-infective and an eczema treatment. Shares rose 1% to 10.3p.
50 Top Movers and Shakers in the BioBusiness World. Cath O'Neill - Following in O@Hara's foot steps! Cath O�Neill, CEO and Founder, SkinBioTherapeutics Cath is passionate about bringing innovation to dermatology. Together with Professor Andrew MacBain at the University of Manchester, she has identified a probiotic, or friendly bacterium from the gut, which can prevent and control diseases in models of skin. The probiotic platform, SKINBIOTIX, enhances the skin�s barrier and is in pre-clinical trials for eczema and anti-infection control. Cath founded the company in 2016 and led SkinBioTherapeutics� �4.5 million IPO in 2017. She also co-founded Curapel, a dermatology business developing natural skin care products, in 2011. Cath is also an academic at the University of Manchester and is deputy associate dean for business engagement.
...conversations with potential commercial partners' Dr Cath O'Neill, chief executive of SkinBioTherapeutics plc (LON:SBTX) tells Proactive it's been a very busy and exciting time for them since IPO'ing on 5 April 2017. ''We've been concentrating on further development of our technology and starting some early conversations with potential commercial partners''. http://www.proactiveinvestors.co.uk/companies/stocktube/7510/skinbiotherapeutics-starting-early-conversations-with-potential-commercial-partners--7510.html
Things appear to be bubbling very nicely. Feels like there could be action soon.
Paying £1.4M of enterprise value for the skills of Adam Reynolds appears to me to be far better value than paying £5 3/4M for the services of C Akers.
Market Cap: £4.5M vs £6.5M Cash: £3.25M vs £750k Management: A Reynolds vs C Akers Orogen PLC would be 10p on the same market cap to cash ratio as Concha PLC. Looks like a bargain!
Great article from Hot Stock Rockets; Is Orogen (LSE:ORE) the cheapest AIM shell? It could well be. That is why with the shares at 1.625p mid, FIML – a company owned by the family trust of Tom Winnifrith, has added to its holding today. As a reminder…. At the current mid the market cap is c£4.3 million. Net cash is more than £3 million. And Adam Reynolds is working hard on a reversal. Most Reynolds reversals whoosh as he does good deals. We expect this to be no different. Look at other shells and you will see how cheap this one is. Concha (LSE:CHA) has cash sub £1 million a track record of value destruction and is valued a £5 million! Nyota (LSE:NYO) has dos all cash and is valued at £1.8 million fully diluted. The idiot money is heading there and will be lost. The smart money buys a few Orogen and waits. Not for long we suspect! Our stance is buy at up to 2.5p. We expect post RTO to be selling at 4p.
Looks great value at these levels, they appear to be at this price due to a persistent seller, once gone these will fly. New CEO - Stuart Bladen - appears to be well respected and has great plans for the future. Lets hope he buys a few shares to show us how serious he is about taking his recent appointment.
1. Well funded 2. Tremendous CEO and Management Team 3. Great Product(s) Just to confirm 109M shares in issue Adam Reynolds said last week "Generating cash within next couple of months" Regulatory approvals for launch in China in place - first order from disturber with payment in advance expected following hospital testing in Q3 this year. Share price move could be similar to OPTI